Bullish
$ONTX The Phase 3-stage biopharmaceutical company said it is in a distribution, license and supply agreement with Knight Therapeutics Inc. , a Canadian-based specialty pharmaceutical company. Under the deal, Knight will have exclusive rights to commercialize Onconova's lead candidate rigosertib in Canada .
  • 4
  • 1